Ovoca Bio reported EUR617K in Selling and Administration Expenses for its fiscal semester ending in December of 2025.





Selling And Administration Expenses Change Date
Akebia Therapeutics USD 23.53M 3.19M Dec/2025
Alaunos Therapeutics USD 447K 138K Mar/2026
ALKERMES USD 196.64M 67.96M Jun/2026
Avita Medical AUD 19.03M 1.95M Dec/2025
Dianthus Therapeutics USD 12.47M 5.89M Mar/2026
Great Western Mining Corporation EUR 595.79K 109.22K Dec/2025
Ionis Pharmaceuticals USD 130.07M 20.92M Jun/2026
IQVIA Holdings USD 574M 72M Jun/2026
Malin Corporation EUR 1.1M 400K Dec/2024
Moderna USD 216M 43M Jun/2026
Organon & Co USD 434M 10M Jun/2026
Ovoca Bio EUR 617K 15K Dec/2025
Revvity USD 278.58M 24.69M Jun/2026
Tectonic Therapeutic USD 6.43M 2.99M Mar/2026
Viatris USD 1.13B 205.7M Jun/2026
Xeris Pharmaceuticals USD 53.14M 10.51M Mar/2026